Pulmonary arterial hypertension (PAH) is a progressive and life-threatening vasculopathy characterized by remodeling of the pulmonary vasculature, ultimately leading to right ventricular (RV) failure and death. Despite significant advancements in pharmacologic therapies over recent decades, current treatments remain insufficient to halt disease progression or significantly extend survival. Existing therapies predominantly target vasodilation, yet fail to address key pathogenic mechanisms, including dysregulated pulmonary vascular metabolism and mitochondrial dysfunction, excessive smooth muscle cell proliferation and apoptosis resistance, extracellular matrix remodeling and stiffening, and endothelial-to-mesenchymal transition.
Over the past decade, epigenetic modifications, defined as heritable or acquired changes that regulate gene expression without altering the underlying DNA sequence, have been increasingly recognized as key contributors to the pathophysiology and progression of cardiovascular diseases. Epigenetic mechanisms act as dynamic sensors, translating environmental cues such as diet, chemical or toxin exposure, medications, stress, and physical activity into gene regulatory changes. Advancements in high-throughput sequencing technologies have accelerated our understanding of how epigenetic dysregulation contributes to a range of chronic conditions. In PAH, accumulating evidence over the last 10 years has implicated multiple layers of epigenetic control in disease pathogenesis. These include aberrant DNA methylation (1); alterations in histone methylation and acetylation (2–7); and dysregulation of non-coding RNAs, including microRNAs (8–12) and long non-coding RNAs [(13–16); Figure 1]. As a result, epigenetics have emerged as a promising field in PAH research, offering new insights into disease mechanisms and novel therapeutic opportunities. Targeting epigenetic alterations holds significant potential as a precision medicine approach, paving the way for innovative, disease-modifying strategies in PAH.
Figure 1
Potential epigenetic therapeutic targets in PAH and RV dysfunction. PAH, pulmonary arterial hypertension; lncRNA, long non-coding RNA; miRNA, microRNA; PA, pulmonary artery; RV, right ventricle. Created with Biorender.
Given the growing recognition of epigenetic dysregulation as a key driver of PAH, this special Research Topic, entitled “Exploring the role of epigenetic modifications in pulmonary vascular disease pathogenesis,” brings together timely contributions that not only synthesize current knowledge but also uncover emerging mechanisms linking epigenetic regulation to vascular remodeling in PAH. In this Research Topic, the review by Ejikeme and Safdar provides a comprehensive overview of the molecular pathways underlying vascular remodeling in PAH, with a particular focus on epigenetic regulators such as DNA methylation, histone methylation and acetylation, and non-coding RNAs. Their work highlights how these epigenetic mechanisms contribute to aberrant smooth muscle and endothelial cell phenotypes characteristic of the PAH vasculature. Importantly, they contextualize these epigenetic changes within broader disease-associated signaling networks, including mitochondrial dysfunction, hypoxia, estrogen signaling, and the BMP/TGF-β axis. Mitra et al. build on this foundation with a more focused review of the central role of hypoxia-inducible factors (HIFs) in modulating epigenetic programs. Their article discusses how hypoxic signaling regulates non-coding RNA expression and alters DNA and histone modifications. Notably, they also explore the reciprocal relationship, wherein epigenetic alterations can feedback to influence HIF stability and activity through post-translational modifications and chromatin remodeling. Finally, Hemnes et al. contribute original research that uncovers a novel link between metabolic reprogramming and epigenetic regulation in PAH. Their study demonstrates that altered lactate handling influences disease progression, supporting emerging evidence that lactylation, a recently described histone modification, may represent a key epigenetic mechanism coupling metabolism to RV dysfunction in PAH.
Beyond synthesizing the current literature on epigenetic modifications in PAH, a central aim of this Research Topic is to highlight critical gaps in our understanding of how environmental and acquired factors interact with genetic predisposition to shape the PAH phenotype through epigenetic mechanisms. Despite progress, major questions remain regarding the extent to which metabolic reprogramming, such as increased lactate production and subsequent histone lactylation, triggers transcriptional programs that drive maladaptive remodeling of the pulmonary vasculature and RV. Further investigation is also needed to elucidate the complex and multifaceted role of sex as a biological variable, particularly in modulating the penetrance and severity of genetic risk via epigenetic regulation. Other pressing gaps include a limited understanding of how acquired risk factors (e.g., obesity, diabetes) and environmental influences (e.g., gut microbiome composition) contribute to disease pathogenesis through epigenetic pathways. Moreover, the safety and therapeutic potential of both broad-spectrum and targeted pharmacologic strategies aimed at modifying epigenetic marks remain largely unexplored. Finally, it is unclear whether the epigenetic mechanisms identified in PAH extend to other forms of pulmonary hypertension, such as those associated with left heart disease or chronic lung disease. We hope this Research Topic serves as a catalyst for future mechanistic research aimed at closing these critical knowledge gaps and advancing the identification of novel therapeutic targets to prevent or mitigate the realization of heritable risk in pulmonary hypertension.
Statements
Author contributions
SP: Writing – original draft, Writing – review & editing. SU: Writing – original draft, Writing – review & editing. FP: Writing – original draft, Writing – review & editing. VA: Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. SP is funded by an American Heart Association Career Development Award (23CDA1049093, https://doi.org/10.58275/AHA.23CDA1049093.pc.gr.167948) and by NIH K08 HL168166. SU is funded by R01HL161038. VA was funded by the Department of Veterans Affairs (IK2BX005828).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
Potus F Pauciulo MW Cook EK Zhu N Hsieh A Welch CL et al . Novel mutations and decreased expression of the epigenetic regulator. Circulation. (2020) 141:1986–2000. 10.1161/CIRCULATIONAHA.119.044320
2.
Cavasin MA Demos-Davies K Horn TR Walker LA Lemon DD Birdsey N et al . Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res. (2012) 110:739–48. 10.1161/CIRCRESAHA.111.258426
3.
Zhao L Chen CN Hajji N Oliver E Cotroneo E Wharton J et al . Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation. (2012) 126:455–67. 10.1161/CIRCULATIONAHA.112.103176
4.
Meloche J Potus F Vaillancourt M Bourgeois A Johnson I Deschamps L et al . Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension. Circ Res. (2015) 117:525–35. 10.1161/CIRCRESAHA.115.307004
5.
Van der Feen DE Kurakula K Tremblay E Boucherat O Bossers GPL Szulcek R et al . Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension. Am J Respir Crit Care Med. (2019) 200:910–20. 10.1164/rccm.201812-2275OC
6.
Habbout K Omura J Awada C Bourgeois A Grobs Y Krishna V et al . Implication of EZH2 in the pro-proliferative and apoptosis-resistant phenotype of pulmonary artery smooth muscle cells in PAH: a transcriptomic and proteomic approach. Int J Mol Sci. (2021) 22:2957. 10.3390/ijms22062957
7.
Chelladurai P Kuenne C Bourgeois A Günther S Valasarajan C Cherian AV et al . Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension. Sci Transl Med. (2022) 14:eabe5407. 10.1126/scitranslmed.abe5407
8.
Parikh VN Jin RC Rabello S Gulbahce N White K Hale A et al . MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation. (2012) 125:1520–32. 10.1161/CIRCULATIONAHA.111.060269
9.
Pullamsetti SS Doebele C Fischer A Savai R Kojonazarov B Dahal BK et al . Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med. (2012) 185:409–19. 10.1164/rccm.201106-1093OC
10.
Bertero T Lu Y Annis S Hale A Bhat B Saggar R et al . Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest. (2014) 124:3514–28. 10.1172/JCI74773
11.
Chen T Zhou Q Tang H Bozkanat M Yuan JX Raj JU et al . miR-17/20 controls prolyl hydroxylase 2 (PHD2)/hypoxia-inducible factor 1 (HIF1) to regulate pulmonary artery smooth muscle cell proliferation. J Am Heart Assoc. (2016) 5:e004510. 10.1161/JAHA.116.004510
12.
Errington N Zhou L Rhodes CJ Fong YL Kariotis S Harder E et al . Diagnostic microRNA signatures to support classification of pulmonary hypertension. Circ Genom Precis Med. (2025) e004862. 10.1161/CIRCGEN.124.004862. [Epub ahead of print].
13.
Wang S Cao W Gao S Nie X Zheng X Xing Y et al . TUG1 regulates pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension. Can J Cardiol. (2019) 35:1534–45. 10.1016/j.cjca.2019.07.630
14.
Hao X Li H Zhang P Yu X Jiang J Chen S . Down-regulation of lncRNA Gas5 promotes hypoxia-induced pulmonary arterial smooth muscle cell proliferation by regulating KCNK3 expression. Eur J Pharmacol. (2020) 889:173618. 10.1016/j.ejphar.2020.173618
15.
Omura J Habbout K Shimauchi T Wu WH Breuils-Bonnet S Tremblay E et al . Identification of long noncoding RNA H19 as a new biomarker and therapeutic target in right ventricular failure in pulmonary arterial hypertension. Circulation. (2020) 142:1464–84. 10.1161/CIRCULATIONAHA.120.047626
16.
Song R Lei S Yang S Wu SJ . LncRNA PAXIP1-AS1 fosters the pathogenesis of pulmonary arterial hypertension via ETS1/WIPF1/RhoA axis. J Cell Mol Med. (2021) 25:7321–34. 10.1111/jcmm.16761
Summary
Keywords
epigenetics, pulmonary arterial hypertension, pulmonary vascular disease, pulmonary hypertension, right ventricle (RV), histone modification, noncoding RNA
Citation
Prisco SZ, Umar S, Potus F and Agrawal V (2025) Editorial: Exploring the role of epigenetic modifications in pulmonary vascular disease pathogenesis. Front. Med. 12:1618278. doi: 10.3389/fmed.2025.1618278
Received
25 April 2025
Accepted
30 April 2025
Published
16 May 2025
Volume
12 - 2025
Edited and reviewed by
Dawei Yang, Fudan University, China
Updates
Copyright
© 2025 Prisco, Umar, Potus and Agrawal.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Francois Potus francois.potus.1@ulaval.ca
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.